WVE Makes A Splash, Mark Your Calendar For ANAB, For Now All's Well With DBVT

DBV Technologies S.A. (DBVT) gained 25.74% on Wednesday, following news that the FDA has accepted the available efficacy and safety data for Viaskin Peanut to be sufficient for the submission of a Biologics License Application for the treatment of peanut allergy in children four to 11 years of age. The submission of BLA for Viaskin Peanut is expected in the second half of 2018.

from RTT - Biotech http://ift.tt/2nXnWHi
via IFTTT